Investigating SNHG3 and BCYRN1 lncRnas expression in the peripheral blood cells of multiple sclerosis patients.

IF 1.7 4区医学 Q3 CLINICAL NEUROLOGY

Neurological Research Pub Date : 2024-09-01 Epub Date: 2024-06-04 DOI:10.1080/01616412.2024.2362585

Samaneh Tayefeh-Gholami, Sama Akbarzadeh, Ali Rajabi, Parisa Najari, Tooraj Ghasemzadeh, MohammadAli HosseinpourFeizi, Reza Safaralizadeh

{"title":"Investigating SNHG3 and BCYRN1 lncRnas expression in the peripheral blood cells of multiple sclerosis patients.","authors":"Samaneh Tayefeh-Gholami, Sama Akbarzadeh, Ali Rajabi, Parisa Najari, Tooraj Ghasemzadeh, MohammadAli HosseinpourFeizi, Reza Safaralizadeh","doi":"10.1080/01616412.2024.2362585","DOIUrl":null,"url":null,"abstract":"Background: MS (Multiple sclerosis) is a progressive neurologic disorder often appearing in the third decade of life. MS is the most frequent demyelinating disease of the central nervous system. The development of MS is influenced by environmental, genetic, and epigenetic factors. The bulk of the human transcriptome comprises lncRNAs, which play crucial regulatory roles. We aimed to assess the SNHG3 and BCYRN1 lncRNA expression in blood samples from MS patients and how these lncRNAs and disease activity are related.Methods: A total of 100 MS patients, including 8 primary progressive (PP), 82 relapsing-remitting (RR), and 10 secondary progressive (SP) MS, as well as 100 healthy controls, had their blood samples taken. Gene expression was assessed using quantitative real-time PCR. Recognizing the receiver operating characteristic (ROC) curve analysis, the diagnostic potential of lncRNA levels was evaluated.Results: Expressions of SNHG3 and BCYRN1 were found to have significantly increased (p < 0.0001). SNHG3 expression level showed significant differences compared to age groups and MS subtypes (p value = 0.001 and p value = 0.02).Furthermore, patients with a family history showed elevated BCYRN1 expression with a p value of 0.01. Considering the age factor, BCYRN1 exhibits altered expression levels in patient groups compared to healthy controls (p value 0.04). Additionally, the novel biomarkers SNHG3 and BCYRN1 can be used to diagnose MS (AUC = 0.97 and AUC = 0.88, respectively).Discussion: Increased levels of SNHG3 and BCYRN1 in the serum may serve as potential molecular biomarkers for the MS diagnosis.","PeriodicalId":19131,"journal":{"name":"Neurological Research","volume":" ","pages":"876-882"},"PeriodicalIF":1.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01616412.2024.2362585","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: MS (Multiple sclerosis) is a progressive neurologic disorder often appearing in the third decade of life. MS is the most frequent demyelinating disease of the central nervous system. The development of MS is influenced by environmental, genetic, and epigenetic factors. The bulk of the human transcriptome comprises lncRNAs, which play crucial regulatory roles. We aimed to assess the SNHG3 and BCYRN1 lncRNA expression in blood samples from MS patients and how these lncRNAs and disease activity are related.

Methods: A total of 100 MS patients, including 8 primary progressive (PP), 82 relapsing-remitting (RR), and 10 secondary progressive (SP) MS, as well as 100 healthy controls, had their blood samples taken. Gene expression was assessed using quantitative real-time PCR. Recognizing the receiver operating characteristic (ROC) curve analysis, the diagnostic potential of lncRNA levels was evaluated.

Results: Expressions of SNHG3 and BCYRN1 were found to have significantly increased (p < 0.0001). SNHG3 expression level showed significant differences compared to age groups and MS subtypes (p value = 0.001 and p value = 0.02).Furthermore, patients with a family history showed elevated BCYRN1 expression with a p value of 0.01. Considering the age factor, BCYRN1 exhibits altered expression levels in patient groups compared to healthy controls (p value 0.04). Additionally, the novel biomarkers SNHG3 and BCYRN1 can be used to diagnose MS (AUC = 0.97 and AUC = 0.88, respectively).

Discussion: Increased levels of SNHG3 and BCYRN1 in the serum may serve as potential molecular biomarkers for the MS diagnosis.

查看原文本刊更多论文

研究多发性硬化症患者外周血细胞中 SNHG3 和 BCYRN1 lncRnas 的表达。

背景：多发性硬化症（MS）是一种进行性神经系统疾病，通常在患者生命的第三个十年出现。多发性硬化症是中枢神经系统最常见的脱髓鞘疾病。多发性硬化症的发病受环境、遗传和表观遗传因素的影响。人类转录组的大部分由 lncRNA 组成，它们起着至关重要的调控作用。我们旨在评估多发性硬化症患者血液样本中SNHG3和BCYRN1 lncRNA的表达，以及这些lncRNA与疾病活动的关系：共采集了100名多发性硬化症患者的血样，包括8名原发性进展期（PP）、82名复发性缓解期（RR）和10名继发性进展期（SP）多发性硬化症患者，以及100名健康对照者。基因表达采用实时定量 PCR 进行评估。通过接收者操作特征曲线（ROC）分析，评估了lncRNA水平的诊断潜力：结果发现，SNHG3和BCYRN1的表达量明显增加（p值=0.001和p值=0.02）。此外，有家族史的患者BCYRN1表达量升高，p值为0.01。考虑到年龄因素，与健康对照组相比，BCYRN1在患者组中的表达水平有所改变（p 值为 0.04）。此外，新型生物标志物 SNHG3 和 BCYRN1 可用于诊断多发性硬化症（AUC = 0.97 和 AUC = 0.88）：讨论：血清中SNHG3和BCYRN1水平的升高可作为诊断多发性硬化症的潜在分子生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurological Research 医学-临床神经学

CiteScore

3.60

自引率

0.00%

发文量

116

审稿时长

5.3 months

期刊介绍： Neurological Research is an international, peer-reviewed journal for reporting both basic and clinical research in the fields of neurosurgery, neurology, neuroengineering and neurosciences. It provides a medium for those who recognize the wider implications of their work and who wish to be informed of the relevant experience of others in related and more distant fields. The scope of the journal includes: •Stem cell applications •Molecular neuroscience •Neuropharmacology •Neuroradiology •Neurochemistry •Biomathematical models •Endovascular neurosurgery •Innovation in neurosurgery.